- CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.
- -
-
Paragraph 000771; 000772
(2018/01/17)
-
- Diphenylparabanic acid as a synthon for the synthesis of α-diketones and α-ketocarboxylic acids
-
Diphenylparabanic acid was found to react with >2 equiv of organolithiums at -78 °C to effectively give the corresponding symmetrical α-diketones. However, upon treatment with 1 equiv of organolithium, the parabanic acid gave mainly 5-substituted 5-hydroxyimidazolidine-2,4-diones. On the other hand, Grignard reagents were less reactive toward the parabanic acid at low temperature, and selectively gave the corresponding 5- hydroxyimidazolidine-2,4-diones even if more than 1 equiv of the reagents was used. A tandem process in which the parabanic acid was first reacted with a Grignard reagent and then reacted in one-pot with an organolithium effectively gave the unsymmetrical α-diketone. 5-Substituted 5-hydroxyimidazolidine-2, 4-diones were useful as versatile precursors for preparing α- ketocarboxylic acids as well as unsymmetrical α-diketones.
- Watanabe, Nobuko,Hamano, Mitsutaka,Todaka, Shota,Asaeda, Takahiro,Ijuin, Hisako K.,Matsumoto, Masakatsu
-
experimental part
p. 632 - 639
(2012/03/22)
-